Abstract
Objectives To compare the clinical characteristics and outcomes of critically ill coronavirus disease (COVID-19) patients requiring mechanical ventilation (MV), receiving interleukin-6 receptor (IL-6R) antagonists, steroids, or a combination of both.
Design An international, multicenter, observational study derived from the COVID-2019 Viral Infection and Respiratory Illness University Study (VIRUS) registry and conducted through the Discovery Network, the Society of Critical Care Medicine. Marginal structural modeling was used to adjust for time-dependent confounders, and observations were weighted using the inverse probability of treatment weight. Sensitivity analysis was conducted to emulate a target trial design.
Setting 168 hospitals in 16 countries.
Patients adult ICU patients (≥ 18 years) requiring MV for COVID-19 between March 01, 2020, and January 10, 2021.
Intervention None.
Measurements and Main Results A total of 860 patients met eligibility criteria: 589 received steroids, 170 IL-6R antagonists, and 101 combination therapy, and the groups were balanced after adjustment. The median daily steroid dose was 7.5 mg dexamethasone or equivalent (IQR: 6–14 mg); 80.8% received low-dose and 19.2% high-dose steroids (> 15 mg/day of dexamethasone or equivalent). The median C-reactive protein level was > 75 mg/L in majority of our cohort. The use of IL-6R antagonists alone or in combination was not associated with a significant difference in ventilator-free days (VFD) compared to steroids alone (adjusted incidence rate ratio [95% CI]): IL-6R antagonists (1.12 [0.88,1.4]), combination (0.83 [0.6,1.14]). Patients treated with low or high-dose steroids had non-significant differences in VFD compared to IL-6R antagonists (ß= 0.62, 95% CI −1.54, 2.78 for low-dose steroid; ß= −1.19, 95% CI −3.85, 1.47 for high-dose steroid). The use of IL-6R antagonists alone or in combination was not associated with a significant difference in 28-day mortality compared to steroids alone (adjusted odds ratio [95% CI]): IL-6R antagonists alone (0.68 [0.44,1.07]), combination (1.07 [0.67,1.7]). There was no difference in hospital mortality compared to steroids alone (aOR 0.68, 95% CI 0.43,1.09 for IL6-R antagonist, aOR 1.23, 95 % CI 0.72,2.11 for combination). The findings of sensitivity analysis were consistent with the primary analysis. The rate of liver dysfunction was higher in the IL-6R antagonist (p=0.038), while the rate of bacteremia did not differ among the three groups.
Conclusions We observed no difference in outcomes between mechanically ventilated adult ICU patients who received IL-6R antagonists, steroids, or combination therapy and those who received IL-6R antagonists or low- or high-dose steroids. Further trials are needed to evaluate high-dose steroids as substitutes for IL-6R antagonists in resource-limited settings.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT04486521
Funding Statement
No external funding was provided for this study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study is approved by the Ethics Committee (office of research affair at King Faisal Specialist Hospital Project ID 2201053), The Society of Critical Care Medicine (SCCM) Scientific Review Committee, and SCCM Discovery Steering Committee. In some participating hospitals, verbal consent was obtained whereas in other countries the requirement for patient consent was waived by local research ethics committees. Local investigators were responsible for obtaining local approval in line with applicable regulations.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
The VIRUS Registry is supported, in part, by the Gordon and Betty Moore Foundation, and Janssen Research & Development, LLC
Data Availability
The datasets used and analyzed during the current report are available from the corresponding author on reasonable request.